These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
452 related articles for article (PubMed ID: 22286807)
1. Cholinesterases, a target of pharmacology and toxicology. Pohanka M Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Sep; 155(3):219-29. PubMed ID: 22286807 [TBL] [Abstract][Full Text] [Related]
3. Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman. Gordon RK; Haigh JR; Garcia GE; Feaster SR; Riel MA; Lenz DE; Aisen PS; Doctor BP Chem Biol Interact; 2005 Dec; 157-158():239-46. PubMed ID: 16256090 [TBL] [Abstract][Full Text] [Related]
4. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission. Duysen EG; Li B; Darvesh S; Lockridge O Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517 [TBL] [Abstract][Full Text] [Related]
5. Diagnoses of Pathological States Based on Acetylcholinesterase and Butyrylcholinesterase. Pohanka M Curr Med Chem; 2020; 27(18):2994-3011. PubMed ID: 30706778 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of two different cholinesterases by tacrine. Ahmed M; Rocha JB; Corrêa M; Mazzanti CM; Zanin RF; Morsch AL; Morsch VM; Schetinger MR Chem Biol Interact; 2006 Aug; 162(2):165-71. PubMed ID: 16860785 [TBL] [Abstract][Full Text] [Related]
7. Crystal structures of human cholinesterases in complex with huprine W and tacrine: elements of specificity for anti-Alzheimer's drugs targeting acetyl- and butyryl-cholinesterase. Nachon F; Carletti E; Ronco C; Trovaslet M; Nicolet Y; Jean L; Renard PY Biochem J; 2013 Aug; 453(3):393-9. PubMed ID: 23679855 [TBL] [Abstract][Full Text] [Related]
8. Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons. Darvesh S; Arora RC; Martin E; Magee D; Hopkins DA; Armour JA Exp Neurol; 2004 Aug; 188(2):461-70. PubMed ID: 15246845 [TBL] [Abstract][Full Text] [Related]
9. The progress in the cholinesterase quantification methods. Holas O; Musilek K; Pohanka M; Kuca K Expert Opin Drug Discov; 2012 Dec; 7(12):1207-23. PubMed ID: 23013366 [TBL] [Abstract][Full Text] [Related]
10. Potency of several oximes to reactivate human acetylcholinesterase and butyrylcholinesterase inhibited by paraoxon in vitro. Jun D; Musilova L; Kuca K; Kassa J; Bajgar J Chem Biol Interact; 2008 Sep; 175(1-3):421-4. PubMed ID: 18617161 [TBL] [Abstract][Full Text] [Related]
11. Inhibitors of Cholinesterases in Pharmacology: the Current Trends. Pohanka M Mini Rev Med Chem; 2020; 20(15):1532-1542. PubMed ID: 31656151 [TBL] [Abstract][Full Text] [Related]
12. Nonquaternary reactivators for organophosphate-inhibited cholinesterases. Kalisiak J; Ralph EC; Cashman JR J Med Chem; 2012 Jan; 55(1):465-74. PubMed ID: 22206546 [TBL] [Abstract][Full Text] [Related]
13. The in vitro protective effects of the three novel nanomolar reversible inhibitors of human cholinesterases against irreversible inhibition by organophosphorous chemical warfare agents. Vitorović-Todorović MD; Worek F; Perdih A; Bauk SĐ; Vujatović TB; Cvijetić IN Chem Biol Interact; 2019 Aug; 309():108714. PubMed ID: 31228470 [TBL] [Abstract][Full Text] [Related]
14. Pharmacology and toxicology of cholinesterase inhibitors: uses and misuses of a common mechanism of action. Pope C; Karanth S; Liu J Environ Toxicol Pharmacol; 2005 May; 19(3):433-46. PubMed ID: 21783509 [TBL] [Abstract][Full Text] [Related]
15. Suitability of human butyrylcholinesterase as therapeutic marker and pseudo catalytic scavenger in organophosphate poisoning: a kinetic analysis. Aurbek N; Thiermann H; Eyer F; Eyer P; Worek F Toxicology; 2009 May; 259(3):133-9. PubMed ID: 19428953 [TBL] [Abstract][Full Text] [Related]
16. [Cholinesterases and their importance in the etiology, diagnosis and therapy of Alzheimer's disease]. Patocka J; Strunecká A; Rípová D Cesk Fysiol; 2001 Feb; 50(1):4-10. PubMed ID: 11268561 [TBL] [Abstract][Full Text] [Related]
17. In vitro kinetic interactions of DEET, pyridostigmine and organophosphorus pesticides with human cholinesterases. Wille T; Thiermann H; Worek F Chem Biol Interact; 2011 Apr; 190(2-3):79-83. PubMed ID: 21354413 [TBL] [Abstract][Full Text] [Related]
18. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase. Pacheco G; Palacios-Esquivel R; Moss DE J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741 [TBL] [Abstract][Full Text] [Related]
19. Cholinesterase inhibition in Alzheimer's disease: is specificity the answer? Macdonald IR; Rockwood K; Martin E; Darvesh S J Alzheimers Dis; 2014; 42(2):379-84. PubMed ID: 24898642 [TBL] [Abstract][Full Text] [Related]
20. Butyrylcholinesterase and the control of synaptic responses in acetylcholinesterase knockout mice. Girard E; Bernard V; Minic J; Chatonnet A; Krejci E; Molgó J Life Sci; 2007 May; 80(24-25):2380-5. PubMed ID: 17467011 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]